OVER DEZE AFLEVERING
A Real Story of Hope, Testing, and Targeted Care.
In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs speaks with Ken Schlosser about how biomarker testing informed his care plan after a stage IV lung cancer diagnosis in 2019.
Ken shares how a routine trip to the ER led to the discovery of an ALK+ alteration, and how comprehensive genomic profiling through OmniSeq helped guide a treatment path that has kept him thriving for more than six years.
They also discuss the role of patient education and advocacy in expanding access to precision testing, as well as why understanding your biomarker status can make a significant difference in care outcomes.
This episode offers an inspiring look at how data-driven decisions can transform lives and why testing is crucial from the outset.
Listen to the full conversation now.
Follow Us
- LinkedIn @labcorp
- X @labcorp
- Facebook @labcorp
- Instagram @labcorp
- YouTube @LabcorpVideo
Presented by Labcorp Oncology
https://www.labcorp.com/oncology
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
